Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28465330 | 0.86 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2589110 | 0.80 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL28866366 | 0.76 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL527776 | 0.73 | HDAC4 (0.45) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9004261 | 0.72 | HDAC4 (0.42) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL944385 | 0.71 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4379605 | 0.70 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13004772 | 0.69 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9797247 | 0.69 | HDAC4 (0.48) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11041604 | 0.69 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2308817-B1 | Minimization of ligand degradation products, or reversion of same to useful phosphine ligands | DOW TECHNOLOGY INVESTMENTS LLC (US) | 2016-10-05 | — | — | EP | disclosed |
| CN-105693498-A | Method for synthesizing alpha, beta-unsaturated acid by using formic acid and alkine | 南开大学 | 2016-06-22 | — | — | CN | disclosed |
| EP-1646599-B1 | MINIMIZATION OF LIGAND DEGRADATION PRODUCTS, OR REVERSION OF SAME TO USEFUL PHOSPHINE LIGANDS | DOW TECHNOLOGY INVESTMENTS LLC (US) | 2015-12-02 | — | — | EP | disclosed |
| EP-2308817-A2 | Minimization of ligand degradation products, or reversion of same to useful phosphine ligands | Dow Technology Investments LLC (US) | 2011-04-13 | — | — | EP | disclosed |
| US-7485759-B2 | Minimization of ligand degradation products, or reversion of same to useful phosphine ligands | DOW TECHNOLOGY INVESTMENTS LLC (US) | 2009-02-03 | — | — | US | disclosed |
| US-20080114191-A1 | MINIMIZATION OF LIGAND DEGRADATION PRODUCTS, OR REVERSION OF SAME TO USEFUL PHOSPHINE LIGANDS | Union Carbide Chemicals & Plastics Technology LLC (formerly Union Carbide Chemicals & Plastics Techn (US) | 2008-05-15 | — | — | US | disclosed |
| US-7351868-B2 | Minimization of ligand degradation products, of reversion of same to useful phosphine ligands | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 2008-04-01 | — | — | US | disclosed |
| US-20070100169-A1 | Minimization of ligand degradation products, of reversion of same to useful phosphine ligands | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY LLC | 2007-05-03 | — | — | US | disclosed |
| EP-1646599-A1 | MINIMIZATION OF LIGAND DEGRADATION PRODUCTS, OR REVERSION OF SAME TO USEFUL PHOSPHINE LIGANDS | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 2006-04-19 | — | — | EP | disclosed |
| WO-2005007602-A1 | MINIMIZATION OF LIGAND DEGRADATION PRODUCTS, OF REVERSION OF SAME TO USEFUL PHOSPHINE LIGANDS | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114191-A1 | MINIMIZATION OF LIGAND DEGRADATION PRODUCTS, OR REVERSION OF SAME TO USEFUL PHOSPHINE LIGANDS | PHOSPHO1, FFAR4, PTGER4 | SLC6A2 3787/4885SLC6A4 2581/4885SLC6A3 4115/4885 |
| US-20070100169-A1 | Minimization of ligand degradation products, of reversion of same to useful phosphine ligands | PHOSPHO1, FFAR4, NOTUM | SLC6A2 3559/4885SLC6A4 2383/4885SLC6A3 3966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.